About ADMA Biologics, Inc.
https://www.admabiologics.comADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
CEO
Adam S. Grossman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 201
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:35.63M
Value:$651.35M
VANGUARD GROUP INC
Shares:20.97M
Value:$383.42M
BLACKROCK INC.
Shares:18.64M
Value:$340.83M
Summary
Showing Top 3 of 405
About ADMA Biologics, Inc.
https://www.admabiologics.comADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $134.22M ▲ | $24.61M ▲ | $36.43M ▲ | 27.14% ▼ | $0.15 ▲ | $51.21M ▲ |
| Q2-2025 | $121.98M ▲ | $24.43M ▼ | $34.22M ▲ | 28.05% ▲ | $0.14 ▲ | $43.99M ▲ |
| Q1-2025 | $114.8M ▼ | $26.22M ▲ | $26.9M ▼ | 23.44% ▼ | $0.11 ▼ | $37.39M ▼ |
| Q4-2024 | $117.55M ▼ | $25.01M ▲ | $111.9M ▲ | 95.19% ▲ | $0.47 ▲ | $39.54M ▼ |
| Q3-2024 | $119.84M | $20.02M | $35.91M | 29.96% | $0.15 | $42.19M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $61.38M ▼ | $568.69M ▲ | $137.5M ▼ | $431.19M ▲ |
| Q2-2025 | $90.28M ▲ | $558.38M ▲ | $160.06M ▲ | $398.32M ▲ |
| Q1-2025 | $71.63M ▼ | $510.57M ▲ | $137.15M ▼ | $373.42M ▲ |
| Q4-2024 | $103.15M ▲ | $488.68M ▲ | $139.66M ▼ | $349.02M ▲ |
| Q3-2024 | $86.71M | $390.62M | $158.73M | $231.89M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $36.43M ▲ | $13.29M ▼ | $-14.37M ▼ | $-27.82M ▼ | $-28.9M ▼ | $-1.07M ▼ |
| Q2-2025 | $34.22M ▲ | $21.14M ▲ | $-2.53M ▲ | $48K ▲ | $18.66M ▲ | $18.72M ▲ |
| Q1-2025 | $26.9M ▼ | $-19.68M ▼ | $-4.72M ▼ | $-7.13M ▲ | $-31.52M ▼ | $-24.38M ▼ |
| Q4-2024 | $111.9M ▲ | $50.22M ▲ | $-2.75M ▼ | $-31.03M ▼ | $16.44M ▲ | $47.46M ▲ |
| Q3-2024 | $35.91M | $25.03M | $-1.1M | $-25.47M | $-1.54M | $23.97M |
Revenue by Products
| Product | Q1-2024 | Q2-2024 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 ADMA BioManufacturing Segment | $80.00M ▲ | $110.00M ▲ | $110.00M ▲ | $120.00M ▲ |
 Corporate Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Plasma Collection Centers Segment | $0 ▲ | $0 ▲ | $10.00M ▲ | $0 ▼ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q3-2025 | Q1-2025 |
|---|---|---|---|---|
 NonUS | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 UNITED STATES | $110.00M ▲ | $120.00M ▲ | $130.00M ▲ | $110.00M ▼ |
 International | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Adam S. Grossman
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 201
Ratings Snapshot
Rating : B
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BLACKROCK, INC.
Shares:35.63M
Value:$651.35M
VANGUARD GROUP INC
Shares:20.97M
Value:$383.42M
BLACKROCK INC.
Shares:18.64M
Value:$340.83M
Summary
Showing Top 3 of 405